
Missed primary efficacy endpoint; fewer events observed in the Brilinta arm but trend did not reach statistical significance Consistent safety profile LONDON, 25-Mar-2016 — /EuropaWire/ — AstraZeneca today announced the top-line results of the SOCRATES trial, assessing the efficacy of Brilinta/Brilique(ticagrelor) 90mg … Read the full press release